HDAC3型
化学
组蛋白脱乙酰基酶
组蛋白脱乙酰酶抑制剂
伏立诺他
乙酰化
药理学
下调和上调
细胞周期
细胞生长
细胞凋亡
细胞毒性
癌症研究
生物化学
体外
组蛋白
生物
基因
作者
Sravani Pulya,Tarun Kumar Patel,Milan Paul,Nilanjan Adhikari,Suvankar Banerjee,Ganesh Routholla,Swati Biswas,Tarun Jha,Balaram Ghosh
标识
DOI:10.1016/j.ejmech.2022.114470
摘要
A promising hydrazide based small molecule lead as a potent and selective histone deacetylase 3 (HDAC3) inhibitor has been developed from a small series of synthesized novel chemical entities. The lead compound (4e) displayed high HDAC3 inhibitory potency (IC50 = 15.41 nM) and a minimum of 18-fold selectivity over other HDAC isoforms. It also exhibited potent cytotoxicity against several cancer cell lines with minimal toxicity against normal cell lines tested. Compound 4e also enhanced acetylation levels on H3K9, H4K12 and H3K27 both in vitro and in vivo. It also induced cell cycle arrest at the G2/M phase in B16F10 and 4T1 cells. It caused significant apoptosis and upregulated the expression of caspase-3, caspase-7, cytochrome c and downregulated the expression of BCL2 in tumour tissue. In addition, the downregulation of CD44, EGFR and Ki-67 suggested the potential of compound 4e in reducing cell proliferation and metastasis in mice. Further, a marked decrease in the tumour volume was observed with no general toxicity in the major organs when treated with 4e in the 4T1-Luc xenograft mouse model. Therefore, compound 4e is a promising candidate selectively targeting HDAC3 with a significant antitumour activity that can be evaluated further in preclinical and clinical evaluation.
科研通智能强力驱动
Strongly Powered by AbleSci AI